CEBPZ and acute myeloid leukemia: More importantly, t(8;21) AML with KIT mutations had a significantly worse prognosis than patients harboring only the translocation, suggesting that KIT mutations might contribute to the outcome and might be considered for risk stratification and therapeutically targetable markers in this subgroup of CBF-AML patients (33).